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the expected annual number of cervical cancer cases (CC) and deaths prevented by HPV 
vaccination of 12-year-old girls in Asian countries (WHO classes) at steady state. Input 
data are, for each country, the incident CC cases and deaths (GLOBOCAN 2002), the 
distribution of HPV types in CC (http://www.who.int/hpvcentre) and the clinical trial 
vaccine efﬁ cacy against CIN2+ related to HPV-16/18 and HPV-31,45,33,52,58,35,
39,51,56,59 combined (cross-protection). Lifetime vaccine protection is assumed. The 
effect of vaccination coverage and the use of alternative estimates for countries without 
sufﬁ cient data are explored. RESULTS: Of 47 countries, sufﬁ cient country-speciﬁ c input 
data are available for eight (China, Japan, Iran, Indonesia, Republic of Korea, Thailand 
and Philippines). The model predicts that, with 100% vaccine coverage, the HPV-16/18 
CC and death reduction ranges from 57% (Japan: −4421 cases; −2032 deaths) to 74% 
(Thailand: −4627 cases; −1942 deaths) while cross-protection related CC and death 
reduction ranges from 9% (Iran; −102 cases, −53 deaths) to 27% (Japan; −2073 cases; 
−953 deaths). The overall reduction ranged from 78% (Iran: −873 cases, −454 deaths) 
to 89% (Indonesia: −13,375 cases; −6724 deaths; Thailand −5534 cases; −2323 deaths). 
With 70% vaccine coverage the CC cases prevented ranges from 611 to 80,052 and CC 
deaths prevented from 318 to 44,921 for Iran and India respectively. Eastern, south-
eastern, southern Asia and Asia continent distributions are available and can be used as 
a proxy for countries without sufﬁ cient HPV data. CONCLUSIONS: Modeling predicts 
HPV vaccination with a bivalent HPV-16/18 vaccine could result in substantial reduc-
tions in CC cases and deaths in Asian countries. Cross-protection could play an impor-
tant role in this reduction. 
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OBJECTIVES: To undertake an economic evaluation of the costs and outcomes of 
midwifery group practice care compared with usual care in an Australian metropolitan 
hospital. METHODS: In a cohort study, pregnant women at low risk of complications 
could select to receive midwifery group practice care or usual care early in their 
pregnancy and were recruited when they were 35 weeks pregnant. Midwifery group 
practice provides care by the same two to three midwives and labor in a birth center. 
Usual care consists of women generally attending a GP or midwives antenatal clinic 
for antenatal care, followed by labor in the hospital. Costing data was collected from 
week 36 of pregnancy until 6 weeks postpartum. Costing for antenatal, labor, baby, 
and postnatal care were collected using the hospital accounting system. Women kept 
a diary with the number of antenatal and postnatal visits. Costing data on GP visits 
were calculated using the diaries and government reimbursement costs. RESULTS: 
The study included 102 women, with 52 women receiving midwifery group practice 
care and 50 women receiving usual care. Midwifery group practice care was associated 
with fewer antenatal visits, lower rate of induction and pharmacological pain relief, 
shorter stay in hospital and more postnatal visits. There were no statistical differences 
in clinical outcomes of the baby. The cost of antenatal care was similar between the 
groups; labor and baby costs were lower for midwifery group practice, while postnatal 
costs were higher in the midwifery group practice. Midwifery group practice was 
associated with a lower total cost per woman compared to usual care (A$4447 vs. 
A$5772, P = 0.047). CONCLUSIONS: For women at low risk of complications 
midwifery group practice is a cost-effective option, with better clinical outcomes and 
lower total costs. 
PIH4
COST OF PUBLIC HEALTH DELIVERY OF CHILDHOOD 
IMMUNIZATIONS IN NOVA SCOTIA
Michaels CL1, Kumaranayke L2, Scott J3, Sarwal S4, Coombs A5, Holmes E6, Sketris IS4
1University of London, London, England, UK; 2Nova Scotia Department of Health, Halifax, 
NS, Canada; 3IWK Health Centre, Halifax, NS, Canada; 4Dalhousie University, Halifax, NS, 
Canada; 5Immunization and Respiratory Infectious Diseases, Centre for Infectious Disease 
Prevention and Control, Halifax, NS, Canada; 6Nova Scotia Health Promotion and 
Protection, Halifax, NS, Canada
OBJECTIVES: Childhood immunizations are recognized as one of the most cost-
effective health interventions. Yet little is know about the actual delivery costs, or 
variation in costs by service providers and geographic regions. This study undertook 
an economic analysis of public health delivery of childhood immunizations in Nova 
Scotia. METHODS: The analysis was performed from the perspective of the govern-
ment health-care provider for a 1-year period from April 2005 to March 2006. An 
incremental approach was used to assess the cost of delivering childhood immuniza-
tions in addition to existing services. Primary cost data collected included capital and 
recurrent costs. Total provider economic costs were estimated using a combination of 
ingredients-based costing and step-down cost allocation methodologies. Sensitivity 
analysis was used to examine the inﬂ uence of data uncertainty on cost results. Mul-
tivariate econometric analysis was used to estimate cost functions. RESULTS: Data 
was collected from four District Health Authorities in Nova Scotia, representing the 
delivery of 2951 immunizations. Average cost per immunization ranged from $51 to 
$105 when delivered in main public health ofﬁ ces and $45 to $150 when delivered 
in off-site clinics. The main cost driver was personnel costs. Econometric analysis 
showed a link between average cost and volume of service delivery. CONCLUSIONS: 
The cost of public health delivery of childhood vaccines varies according to the volume 
of services delivered and the delivery setting. The approach developed can be applied 
to the introduction of new vaccines such as human papilloma virus. Public health 
delivery of vaccines can be efﬁ cient if programmed on the appropriate scale. 
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OBJECTIVES: To investigate medical cost and health resource utilization for patients 
with postpartum hemorrhage (PPH) in Korea in 2008. METHODS: This population-
based study utilized the claims data of the Korea Health Insurance Review Agency 
from January 2008 to December 2008. Patients with PPH were identiﬁ ed based on 
ICD-10 code (O72, O721, O722, O723) that occurred within 6 weeks after normal 
or cesarean delivery. Treatments for PPH were classiﬁ ed into four categories: uterine 
contraction drugs only, drugs and transfusion, drugs + transfusion + uterine artery 
embolization (UAE), and drugs + transfusion + hysterectomy. Medical costs for PPH 
patients included all costs incurred for delivery and treating PPH. Costs and length of 
stay were analyzed in regard to the mode of delivery, age, and type of hospital where 
the delivery took place. Data were analyzed using SAS. RESULTS: There were 18,142 
(4%) PPH patients out of 452,219 deliveries in Korea in 2008. The medical cost (mean 
± SD) in patients who underwent normal delivery (ND) without PPH was 610 ± 153 
US$ and 758 ± 859 US$ for patients with PPH. The medical cost in patients who 
underwent cesarean delivery (CD) without PPH was 973 ± 1403 US$ and 860 ± 511 
US$ for patients with PPH. Length of stays (mean ± SD) were 3.7 ± 1.8 days, 3.3 ± 
0.7 days, 7.7 ± 8.8 days and 7.1 ± 3.2 days for ND with PPH patients, ND without 
PPH patients, CD with PPH patients, and CD without PPH patients, respectively. The 
mean medical cost of patients who were treated with drugs only, drugs and transfu-
sion, drugs + transfusion + UAE, and drugs + transfusion + hysterectomy were 
US$628, US$1028, US$3850, and US$3501, respectively. CONCLUSIONS: The 
medical cost was higher in patients with PPH compared to patients without PPH. 
Although the medical cost of treating PPH with UAE is higher than that of hysterec-
tomy, preserving fertility seems well worth the additional cost. 
PIH6
BUDGET IMPACT ANALYSIS OF INCLUDING LIVER 
TRANSPLANTATION IN CHILDREN INTO THE UNIVERSAL COVERAGE 
BENEFIT PACKAGE OF THAILAND
Pachanee K1, Prakongsai P2
International Health Policy Program (IHPP), Nonthaburi, Thailand, 2International Health 
Policy Program (IHPP), Nonthaburi Province, Thailand
BACKGROUND: Liver transplantation in children is an expensive health service 
excluded from the beneﬁ t package of the universal coverage (UC) scheme, which 
covers 47 million of Thais. Its high costs and exclusion from the UC beneﬁ t package 
prevent poor biliary atresia (BA) patients from access to such health care. OBJEC-
TIVES: This study aims to estimate ﬁ nancial impact of including liver transplantation 
in children in the UC beneﬁ t package. It also explores demand for, and supply of, and 
ﬁ nancial feasibility in implementing universal access to such expensive health care in 
Thailand. METHODS: Methods include comprehensive literature review, in-depth 
interviews of medical specialists in liver transplantation in three university hospitals 
about incurred costs during and after operations, and modeling budget requirements 
for expanding universal access to such medical care. RESULTS: Research ﬁ ndings 
indicate that the incidence of BA patients in Thailand is approximately 1 to 15,000 
of live births, approximately 60 new cases of BA patient annually. Only three univer-
sity hospitals in Thailand can provide liver transplantation to children with the annual 
maximum surgical capacity of 40 cases. Literature shows the survival rate of BA 
children receiving liver transplantation ranges from 83% to 94% in the ﬁ rst year, and 
82% to 92% in the ﬁ fth year. Costs of liver transplantation in the ﬁ rst year are 
approximately 1 million Baht (US$30,000). Other costs after the ﬁ rst year including 
immunosuppressive drugs and prophylaxis antibiotics range from US$360–600 per 
month. The government will spend approximately 40 million Baht in the ﬁ rst year of 
implementation. The ﬁ nancial burden will increase to 184 and 328 million Baht per 
year in the year 30th and 70th, respectively. CONCLUSIONS: The budget require-
ment for this medical care is trivial compared to the total UC budget, but can save 
lives of BA patients and improve equity in access to health care. 
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OBJECTIVES: Cervical cancers are the second highest incidence of female cancers in 
Malaysia, causing high impact on nation’s health cost and patient’s quality of life that 
can be avoided by better screening and HPV vaccination. METHODS: This is a cross 
sectional study done from 2006–2009 and respondents were interviewed from six 
public hospitals. Methods include experts’ panel discussions to estimate treatment 
costs and respondents’ interviews using costing and SF-36 quality of life (QOL) 
questionnaires. Three programs options were compared i.e., Pap smear screening; 
quadrivalent HPV vaccination and combined strategy (screening plus vaccination). 
RESULTS: Five hundred two cervical cancer patients participated in the study. Mean 
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age was 53.3 ± 11.21 years, educated till secondary level (39.4%), Malays (44.2%) 
and married for 27.73 ± 12.12 years. Life expectancy gained from vaccination is 13.04 
years and average Quality Adjusted Life-years saved (QALYs) is 24.40 in vaccinated 
versus 6.29 in unvaccinated women. Cost/QALYs saved for Pap smear at base case is 
RM 1214.96/QALYs and RM 1100.01/QALYs at increased screening coverage. In 
HPV vaccination, base case is at RM 35,346.79/QALYs and RM 46,530.08/QALYs 
when vaccination price is increased. In combined strategy, cost/QALYs at base case 
is RM 11,289.58/QALYs; RM 7712.74/QALYs at best case and RM 14,590.37/
QALYs at worst case scenario. Incremental cost-effectiveness ratio (ICER) showed 
that screening at 70% coverage or higher is highly cost effective at RM 946.74 per 
QALYs saved and this is followed by combined strategy at RM 35,346.67 per QALYs 
saved. Budget impact analysis indicated that it cost the government RM 180.4 million 
per year and 2.5% of the national health budget. CONCLUSIONS: Vaccination 
increase life expectancy with better QOL. Cost effective strategies will include increas-
ing the Pap smear coverage to 70% or higher. Since feasibility and long term screening 
adherence is doubtful among Malaysian women; vaccination of young women is more 
cost effective strategy against cervical cancer. 
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OBJECTIVES: The quadrivalent (6,11,16,18) HPV vaccine has been approved in 
Thailand for prevention of cervical cancer, vulvar/vaginal pre-cancers, and genital 
warts in women age 9 to 26 years. To assess the health and economic impact of the 
quadrivalent (6,11,16,18) HPV vaccine in Thailand. METHODS: A published math-
ematical model of the transmission dynamics of HPV infection and disease was 
adapted for Thailand. Model inputs were used from Thailand or the Asia/Paciﬁ c 
region when available; otherwise, the default values in the original model were used. 
Maintaining current cervical cancer screening practices in Thailand, we evaluated two 
strategies: routine vaccination of females by age 12 (S1), and S1 combined with a 
temporary (5 years) female catch-up program for age 12–24 years (S2). The vaccine 
coverage rates were 70% for the routine and 50% for the catch-up vaccination pro-
grams. The perspective of analysis was health-care system. RESULTS: The most 
effective strategy was S2. Using this strategy over 100 years in the population of 
Thailand, the estimated cumulative percent reduction in incident HPV 6/11/16/18-
related genital warts-female, genital warts-male, cervical intraepithelial neoplasia 
(CIN) grade 1, CIN 2/3, and cervical cancer cases was 72%, 55%, 61%, 63%, and 
48%, respectively. The cost-effectiveness ratios were Thai Baht 145,447 or US$4,453 
(weakly dominated), and Thai Baht 131,845 or US$4,036 per quality-adjusted life-
years (QALY) gained for S1 and S2 compared with no vaccination, respectively. 
CONCLUSIONS: In Thailand, vaccination of females age 12–24 years with a quad-
rivalent (6,11,16,18) HPV vaccine can reduce the incidence of cervical cancer, CIN, 
and genital warts at a cost per QALY ratio within the range typically regarded as 
cost-effective. 
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OBJECTIVES: To estimate the relative cost effectiveness of available contraceptives 
in a paciﬁ c region country (Colombia) from a social perspective. METHODS: A 
Markov model was constructed to simulate costs for 13 contraceptive methods and 
for no contraceptive method over a 10-year period, with a 5% discount rate. Failure 
rates, adverse event rates and resource utilization were derived from literature. Sensi-
tivity analyses were performed on costs and effectiveness rates. RESULTS: The four 
least expensive methods per person month were: copper-T IUD (USD $0.34), vasec-
tomy (USD $1.28), tubal ligation (USD $1.44) and implant (USD $2.19). The cost-
effectiveness analysis of methods to prevent pregnancy showed: the Copper T IUD 
has a ratio of incremental cost-effectiveness (ICER) of USD $5,540 (per month, per 
pregnancy avoided) when it is contrasted with the vasectomy. The Vasectomy is 
dominant compared to tubal ligation, and it presents an ICER of USD $7.371 in 
relation to implant methods. Comparing Copper T with the second most affordable 
reversible method, an ICER of USD $12,033 was obtained. The order of results did 
not change with a discount rate of 0% but were sensitive to the time horizon. CON-
CLUSIONS: Differences in time horizon are inﬂ uential factors that determine the 
dominance of contraceptive methods. It is noteworthy that although the cost of a tubal 
ligation and a vasectomy is the same, the total costs for a vasectomy are lower due 
to reduced complication-related costs. Given that the monthly premium of the com-
pulsory health insurance in Colombia for a woman of childbearing age (19–44 years) 
is USD$22, the value of USD$12,033 or $5540 per month to prevent pregnancy 
through implant or vasectomy is excessive. Therefore, according to the case analysis, 
the Copper T is a cost-effective option for Colombia, including reversible and nonre-
versible methods. 
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OBJECTIVES: Cervical cancer is the second highest incidence of female cancers in 
Malaysia. This can be avoided by Pap smear screening and Human Papillomavirus 
(HPV) vaccination i.e., the bivalent vaccine (BV) and quadrivalent (QV). Three 
programs cost effectiveness (CE) options were compared i.e., screening via Pap smear; 
modeling of HPV vaccination (QV and BV) and combined strategy (screening plus 
vaccination). Scenario based sensitivity analysis using screening population coverage 
(40–80%) and costs of vaccine (RM 100–200/dose) were calculated. METHODS: This 
is a cross sectional study from 2006–2009 and respondents were interviewed from six 
public Gynecology–Oncology hospitals. Methods include experts’ panel discussions 
to estimate treatment costs by severity and direct interviews with respondents using 
costing and quality of life questionnaires. RESULTS: A total of 502 cervical cancer 
patients participated with mean age at 53.3 ± 11.21 years, Malays (44.2%) and 
married for 27.73 ± 12.12 years. Cost/QALYs for Pap smear at base case is RM 
1,214.96/QALYs and RM 1,100.01/QALYs at increased screening coverage. In QV 
only, cost/QALYs saved in base case are at RM 15,662/QALYs and RM 24,203/
QALYs when vaccination price is increased. In BV only; cost/QALYs saved in base 
case is at RM 1359,057/QALYs and RM 2530,017.56/QALYs when vaccination price 
is increased. In QV combined strategy cost/QALYs at base case is RM 4937/QALYs; 
RM 3395/QALYs at best case and RM 7992/QALYs at worst case scenario. In BV 
combined strategy, cost/QALYs at base case is RM 6624/QALYs; RM 4033/QALYs 
at best case and RM 10,543/QALYs at worst case scenario. Incremental cost-
effectiveness ratio (ICER) showed that screening at 70% coverage or higher is highly 
cost effective at RM 946.74 per QALYs saved and this is followed by best case com-
bined strategy with QV at RM 13,000 per QALYs saved. CONCLUSIONS: QV is 
more cost effective than BV. The QV combined strategy is more CE than any method 
except Pap smear screening at high population coverage. 
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OBJECTIVES: Raloxifene (RLX) reduces the risk of vertebral fractures and invasive 
breast cancer (IBC). The National Osteoporosis Foundation (NOF) has recommended 
a threshold for treatment initiation of 10-year major fracture risk of 20%, but given 
RLX’s beneﬁ cial efﬁ cacy on IBC it may be clinically beneﬁ cial and cost-effective to 
treat women with RLX even if they do not meet this threshold. The aim was to identify 
how 5-year IBC risk affects the cost-effectiveness of treating younger postmenopausal 
women who do not meet the 20% absolute fracture risk threshold with RLX com-
pared to no intervention. METHODS: A micro-simulation model populated with data 
speciﬁ c to American women was used to quantify the costs and beneﬁ ts of 5-year 
treatment with RLX from a societal perspective. Possible events were vertebral frac-
ture, IBC, VTE and death. EQ-5D societal health state values were used to estimate 
quality-adjusted life-years (QALYs). The population was selected based on 10-year 
major fracture risk as estimated with FRAX® (5–19.9%) and 5-year IBC risk as 
estimated with Gail risk model (1–5%). RESULTS: The cost per QALY gained ranged 
from US$17,100 to 93,000. RLX was progressively cost-effective with increasing 
fracture risk and IBC risk holding age constant. At lower fracture risk in combination 
with lower IBC risk or when no preventive RLX effect on IBC was assumed, the 
cost-effectiveness of RLX decreased markedly and was not cost-effective given a 
willingness-to-pay of US$50,000. At fracture risk of 15–19.9% RLX was cost-effective 
also in women at lower IBC risk. CONCLUSIONS: RLX is potentially cost-effective 
in young postmenopausal women at elevated IBC risk who do not meet the suggested 
NOF 10-year fracture threshold. This highlights the importance of considering a 
woman’s full risk proﬁ le when deciding which anti-osteoporosis treatment to 
recommend. 
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OBJECTIVES: The study evaluated the cost effectiveness of the bivalent AS04 adju-
vant vaccine in Slovakia and the correlation between vaccine protection duration and 
incremental cost effectiveness of HPV vaccination of 12-year-old girls with bivalent 
AS04 adjuvant vaccine in Slovakia. METHODS: A 1-year cycle Markov model (20—
health state) used age-speciﬁ c data on dysplasia or cervical cancer. A base case analysis 
assumed 98% vaccine efﬁ cacy against HPV—16/18 and 50% vaccination coverage. 
